Company Filing History:
1 out of 16 
1 out of 150 
Years Active: 1995
Title: The Innovations of Jeffrey P. Golder
Introduction
Jeffrey P. Golder is an accomplished inventor based in Mona Vale, Australia. He is known for his significant contributions to the field of biotechnology, particularly in the development of proteins that play a crucial role in cancer research and treatment.
Latest Patents
One of Golder's notable patents is for Human PAI-2, also known as Minactivin. This protein acts as an inactivator of urokinase-type plasminogen activator, which is associated with invasive tumors. The patent highlights the importance of Minactivin as a natural inactivator that aids the body's defense against tumor invasion and metastasis. The production of this protein can be achieved through the cultivation of minactivin-producing cells in vitro, allowing for the recovery of the cell culture supernatant. By controlling the culture conditions, Minactivin can be produced in a partially purified form, which may be utilized for the diagnosis and treatment of tumors. The patent also discloses methods for the purification of biologically active native Minactivin, as well as peptides derived from it and their amino acid sequences. Furthermore, it details the production of PAI-2 using recombinant DNA technology, characterization of the PAI-2 gene sequence, and the expression and purification of large quantities of biologically active PAI-2 from a recombinant host.
Career Highlights
Throughout his career, Golder has worked with prominent organizations such as Biotechnology Australia Pty Ltd and The Australian National University. His work has significantly advanced the understanding of tumor biology and the development of therapeutic strategies.
Collaborations
Golder has collaborated with notable colleagues, including Ross W. Stephens and Toni Marie Antalis, contributing to the advancement of research in his field.
Conclusion
Jeffrey P. Golder's innovative work in biotechnology, particularly with his patent on Human PAI-2, showcases his dedication to improving cancer treatment and understanding tumor biology. His contributions continue to have a lasting impact on the field.